Charalampos Tzoulis | |
---|---|
![]() | |
Born | 27 December 1979 Athens, Greece |
Known for | Parkinson's disease research |
Website | www.decode-pd.org |
Charalampos (Haris) Tzoulis is an internationally recognized expert in movement disorders and neurodegenerative diseases who has made several scientific contributions, especially in the understanding of mitochondrial dysfunction and NAD metabolism in Parkinson's disease.
Tzoulis was born in Athens, Greece, studied medicine in Szeged, Hungary, and completed his specialization in neurology at Haukeland University Hospital, Bergen, Norway. In 2010 he obtained his PhD at the University of Bergen with the project: "Clinical and Molecular studies of Mitochondrial DNA Polymerase Gamma (POLG) Associated Disease". [1] Currently,[ when? ], he is Professor of Neurology and Neurogenetics at the University of Bergen and Senior Consultant of Neurology at the Department of Neurology, Haukeland University Hospital.
He leads the research group "DECODE-PD", [2] a transdisciplinary team of over 40 members focusing on translational and clinical research with the goal to develop and test new biomarkers and treatments for Parkinson's disease and related disorders. Their work comprises investigator-driven multicenter clinical trials, including a multi-arm multi-stage platform enabling parallel testing of multiple potential disease-modifying compounds.
Tzoulis is director of the Neuro-SysMed National Center for Clinical Treatment Research in neurological diseases, [3] and director of the K.G. Jebsen Center for Translational Research in Parkinson's disease. [4]
Tzoulis is the head of the Neurodegeneration Research Program and principal investigator for Parkinson's disease at the Neuro-SysMed Center. Neuro-SysMed is funded by the Norwegian Research Council [5] and conducts clinical research on four neurological disease-groups: Parkinson's disease and related disorders, amyotrophic lateral sclerosis, dementia disorders, including Alzheimer’s disease and dementia with Lewy bodies, and multiple sclerosis.
The overarching goal of the K.G. Jebsen Centre for Parkinson’s disease is to elucidate mechanisms driving the initiation and progression of Parkinson’s disease and related disorders and to identify molecular disease subtypes, so that tailored treatment may be developed and tested. This will enable design and test targeted therapies for each emerging molecular disease subtype, thus setting the foundation for tailored, personalized medicine for individuals with Parkinson's disease. The center is funded by the K.G. Jebsen Foundation [6] together with the University of Bergen.
Tzoulis has led multiple publications in the field of neurodegeneration. [7]